Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model.

Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model.
复制标题

Juzentaihoto 对 B16 黑色素瘤转移模型中肿瘤免疫治疗的功效。

DOI:
10.1155/2017/6054706
复制
发表时间:
2017
期刊:
Evidence-based complementary and alternative medicine : eCAM
影响因子:
--
通讯作者:
Hisamitsu T
Hisamitsu T
中科院分区:
其他
文献类型:
--
作者:
Ishikawa S;Ishikawa T;Tezuka C;Asano K;Sunagawa M;Hisamitsu T

文献摘要

被引文献

相似文献

导论.日本癌症患者的医疗保健包括西药和汉方药物,据报道,juzentaihoto(JTT)治疗可预防癌症转移和复发。在这项研究中,我们检查了JTT对自然杀伤(NK)细胞活性和转移的影响,在黑色素瘤转移的小鼠模型中与抗PD-1抗体联合治疗。方法. C57 BL/6雄性小鼠静脉内注射B16黑素瘤细胞(B16细胞),并给予含有3%JTT的食物。在随后的体内实验中,我们评估了血清细胞因子水平和肺中的肿瘤集落形成。此外,我们在离体实验中评估了NK细胞活性。结果JTT显著抑制B16细胞转移,而将抗去唾液酸-GM 1抗体注射到小鼠中废除JTT的抑制作用。JTT显著提高血清中IL-12和IFN-γ水平,并诱导NK细胞活性。增强抗PD-1抗体对B16细胞转移的抑制作用。讨论这些数据表明JTT通过诱导NK细胞活性来抑制B16细胞转移。此外,JTT和抗PD-1抗体的联合治疗增加了B16黑色素瘤的治疗应答率。
Introduction. Medical care for Japanese cancer patients includes Western and Kampo medicines, and treatments with juzentaihoto (JTT) reportedly prevent cancer metastasis and recurrence. In this study, we examined the effects of JTT on natural killer (NK) cell activity and metastasis in combined treatments with anti-PD-1 antibody in a mouse model of melanoma metastasis. Methods. C57BL/6 male mice were intravenously injected with B16 melanoma cells (B16 cell) and were given chow containing 3% JTT. In subsequent in vivo experiments, we assessed serum cytokine levels and tumor colony formation in the lungs. Additionally, we assessed NK cell activity in ex vivo experiments. Results. JTT significantly suppressed B16 cell metastasis, whereas injection of anti-asialo-GM1 antibody into mice abrogated the inhibitory actions of JTT. JTT significantly increased interleukin- (IL-) 12 and interferon- (IFN-) γ levels in serum and induced NK cell activity. It increased the inhibitory actions of the anti-PD-1 antibody on B16 cell metastasis. Discussion. These data suggest that JTT inhibits B16 cell metastasis by inducing NK cell activity. Additionally, combination therapy with JTT and anti-PD-1 antibody increased treatment response rates for B16 melanoma.